INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results.

David A. Reardon,Steven Brem,Arati Desai,Stephen J. Bagley,Sylvia Kurz,Macarena I. de la Fuente,Seema Nagpal,Mary Welch,Adilia Hormigo,Nicholas Carroll,Sarah K Bartra,Patricia Campbell,Kamalnayan Bhatt,Israel Lowy,Jean D. Boyer,Kimberly A. Kraynyak,Matthew P. Morrow,Trevor McMullan,David B. Weiner,Jeffrey Skolnik

INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results.

2020

2514Background: Novel T cell-enabling therapies, in combination with checkpoint inhibition, may improve OS in GBM. INO-5401 (synthetic DNA plasmids encoding for hTERT, WT-1 and PSMA), plus INO-9012...

Keywords:

Oncology
Electroporation
newly diagnosed
Glioblastoma
Interim
Pathology
Internal medicine
Medicine
Telomerase reverse transcriptase
immune checkpoint inhibitors
Synthetic DNA
Plasmid
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations